




MDH-015 for the treatment of Intractable Ocular Disease

MDH-015 (*Lactobacillus paracasei* EV) is a new class of first-in-class oral therapeutic indicated for intractable ocular diseases, such as wet & dry forms of age-related macular degeneration (wet & dry AMD), diabetic retinopathy, and more

MDH-015

- Naïve (natural) EVs from a single **Lactobacillus** strain



Value Propositions

1. **First-in-class:** a new modality drug with a novel mechanism of action (MoA)
2. **Very safe:** a safe commensal bacterium *Lactobacillus paracasei*-derived EVs
3. **Effective:** a disease-modifying therapy against intractable ocular diseases, including dry AMD, wet AMD, and diabetic retinopathy
4. **Convenient administration:** orally-delivered
5. **Affordable:** cost effective production

MDH-015: Key Indications & Development Timeline

Key Indications

- 1) **Dry AMD (age-related macular degeneration)**
- 2) **Wet AMD (age-related macular degeneration)**
- 3) **Diabetic retinopathy**
- 4) Glaucoma

Core patent

- ✓ PCT (KR2021/013717) application date at 06/Oct/2021
- ✓ Registered at US (as of July 2022)

Development Timeline

IND filing ('22)



P1 ('23)



P2 ('25)



Exit